Estriol 0.01% cream

Estriol 0.01 % cream can be prescribed as hormone replacement therapy for the treatment of atrophic vaginitis and kraurosis in postmenopausal women and, for the treatment of pruritus vulvae and dyspareunia associated with atrophic vaginal epithelium.1

Please click here to view estriol 0.01 % prescribing information

Treatment

NICE recommendations:2

  • Offer vaginal oestrogen to women with urogenital atrophy (including those on systemic HRT) and continue treatment for as long as needed to relieve symptoms
  • Consider vaginal oestrogen for women with urogenital atrophy in whom systemic HRT is contraindicated
  • If vaginal oestrogen does not relieve symptoms of urogenital atrophy, consider increasing the dose

NICE advises explaining to women with urogenital atrophy that:2

  • Symptoms often come back when treatment is stopped
  • Adverse effects from vaginal oestrogen are very rare
  • They should report unscheduled vaginal bleeding

How to apply estriol 0.01% cream

  • 1
    Remove the cap from the tube. Use the top of the cap to pierce the metal seal on the tube.
  • 2
    One end of the applicator has a plunger, screw the other end of the applicator onto the tube.
  • 3
    Squeeze the tube so that the applicator barrel is completely filled with cream. This will pull the plunger out.
  • 4
    Unscrew the filled applicator and replace the cap on the tube.
  • 5
    Lie down with your knees bent and spread apart.
  • 6
    Gently insert the open end of the applicator well into your vagina.
  • 7
    Push the plunger firmly but gently. Empty the cream into your vagina by pushing the plunger as far as it will go.
  • 8
    Keep the plunger firmly pressed down. Grip the applicator by the barrel and remove the empty applicator.
  • 9
    Wash your hands afterwards.
  • 10
    Use a sanitary towel to stop your clothes getting stained.
  • Note: estriol 0.01% cream contains peanut oil.

Breast pain, increased micturition frequency, vaginal discharge, cystitis, leg pain, pre-menstrual tension, lower abdominal pain, palpitations and depression have been reported in a placebo controlled trial with this estriol formulation.

Estriol should not be applied by patients known to be allergic to peanuts or soya. For further information on contraindications, warning and precautions, and interactions, please refer to the Summary of Product Characteristics by clicking here.1

Adverse events should be reported

Adverse events should be reported. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google Play or Apple App Store. Adverse events should also be reported to Marlborough Pharmaceuticals Ltd. on +44 (0) 1279 406759 or by email to atnahspv@diamondpharmaservices.com.